Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
|Articles|November 9, 1994
Gendex piques Picker's interest
Multimodality vendor Picker Internationalmay be a potential suitor for x-ray and mammography vendor Gendex,which was put on the block last month by owner Dentsply International(SCAN 10/26/94). Picker is "interested" in Gendex, accordingto
Advertisement
Multimodality vendor Picker Internationalmay be a potential suitor for x-ray and mammography vendor Gendex,which was put on the block last month by owner Dentsply International(SCAN 10/26/94). Picker is "interested" in Gendex, accordingto spokesperson Mike Peterson. He declined to elaborate further.
Dentsply announced in October that it plans to divest its medicaloperations and focus on its core dental business. Dentsply signedan agreement to sell x-ray tube manufacturer Eureka X-Ray Tubeto Varian Associates.
In other Picker news, the Cleveland vendor announced that ithas acquired the manufacturing and distribution rights to KubotaGraphics' Denali 3-D graphics processor. The processor is integratedwith Digital Equipment's Alpha hardware in Picker's Odyssey VPnuclear medicine workstation. The acquisition should improve Picker'sposition in complex 3-D display, particularly in nuclear cardiologyapplications, according to the company.
Advertisement
Related to this article
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.
Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?
Catch up on a variety of FDA news in radiology from the past week.
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears AI-Powered Triage Software for 10 Findings on Abdominopelvic CT
2
FDA Grants Final Approval of Emerging Radiopharmaceutical for GEP-NET Treatment
3
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
4
Is Private Practice Radiology as Important as an Amusement Park?
5